Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Overview of the included studies

From: A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks—results from the Lassa fever pilot

Domain No. of extracted studies Setting* No. of participants Populations Study objectives Intervention
Clinical phenotype and natural history of disease 25 14 Nigeria
7 Sierra Leone
3 Liberia
3 Mali
1 USA
Total: n = 6680 LF pos. n = 1734 Adults
Pregnant women
Children, Infants, Neonates
(0 to > 65 years old)
Clinical presentation, symptoms (n = 15)
LF fatality rate (n = 11)
Biochemical laboratory parameters (n = 7)
N/A
Transmission and prevention 12 5 Sierra Leone
4 Nigeria
1 Germany
1 Liberia
1 UK
1 USA
Total: n = 1980 LF pos: n = 281 Adults
Pregnant women
Children, Infants, Neonates
(0 to 73 years)
Ribavirin as PEP (n = 4)
Risk of nosocomial transmission (n = 5)
Ribavirin
Diagnostics 7 4 Sierra Leone
2 Liberia
1 Nigeria
Total: n = 3338 LF pos: n = 897 Adults
Children
PCR for diagnostics (n = 3) PCR and hybridization (n = 1)
LFI, ELISA and PCR (n = 1)
IgM as early marker (n = 1)
PCR, LFI, ELISA, virus isolation
Immune response 5 2 Guinea
2 Sierra Leone
1 Liberia
1 Mali
Total: n = 4570 LF pos: n = 1437 Adults
Children, Infants
(7 months to 83 years)
Levels of inflammatory cytokines chemokines and other pro-inflammatory mediators (n = 1)
Prevalence of LASV-specific IgG antibodies (LV IgG) (n = 1)
Population LF seroconversion (n = 1)
 
Drug therapy and supportive care 10 4 Nigeria
4 Sierra Leone
2 USA
1 Germany
Total: n = 1516 LF pos: n = 792 Adults
Pregnant women
Children, Infants, Neonates
(0 to 65 years)
Therapeutic effectiveness of Ribavirin (n = 9)
Therapeutic effectiveness of LF convalescent plasma therapy (n = 2)
Ribavirin treatment adverse event (n = 1)
Ribavirin iv.
Ribavirin oral
Convalescent plasma
Risk factors for more severe disease 4 3 Sierra Leone
2 Guinea
Total: n = 2110 LF pos. or probable: n = 562 Adults
Pregnant women Children, Infants, Neonates
(0 to > 60 years)
Correlation of cytokine levels and outcome (n = 2)
Correlation of AST and outcomes (n = 1)
Correlation of BUN, ALP, ALT, and outcomes (n = 1)
Correlation of viremia level and outcome (n = 1)
Risk factors for positive LASV IgG (n = 1)
 
  1. Abbreviations: LF Lassa fever, LASV Lassa virus, Pos positive, PEP post-exposure prophylaxis, PCR polymerase chain reaction, LFI lateral flow immunoassay, ELISA enzyme-linked immunosorbent assay, Ig immunoglobulin, AST aspartate aminotransferase, BUN blood urea nitrogen, ALP alkaline phosphatase, ALT alanine aminotransferase
  2. *Some studies were set in more than one country